NOTE In this Registration Document, the terms “Company,” “GenSight tense, or by the use of forward-looking terms such as “considers,” Biologics,” “we,” “us” and “our” mean GenSight Biologics S.A. All “envisages,” “believes,” “aims,” “expects,” “intends,” “should,” references herein to “$” are to United States dollars, the currency “anticipates,” “estimates,” “thinks,” “wishes” and “might,” or, if of the United States of America. applicable, the negative form of such terms and similar expressions This Registration Document describes the Company as of the or similar terminology. Such information is not historical in date hereof. nature and should not be interpreted as a guarantee of future performance. Such information is based on data, assumptions, This Registration Document includes our annual financial and estimates that we consider reasonable. Such information is statements prepared in accordance with French accounting subject to change or modification based on uncertainties in the standards for the fiscal year ended December 31, 2017. In economic, financial, competitive or regulatory environments. This accordance with provisions of Article 28 of the Commission information is contained in several sections of this Registration Regulation (EC) No 809/2004 of April 29, 2004, as amended, the Document and includes statements relating to our intentions, Company’s annual financial statements prepared in accordance estimates and targets with respect to our markets, strategies, with French accounting standards for the fiscal years ended growth, results of operations, financial situation and liquidity. December 31, 2015 and 2016 and the statutory auditor’s Our forward-looking statements speak only as of the date of this reports on the Company’s annual financial statements prepared Registration Document. Absent any applicable legal or regulatory in accordance with French accounting standards for the fiscal requirements, we expressly disclaim any obligation to release years ended December 31, 2015 and 2016 included in the any updates to any forward-looking statements contained in this Registration Document registered with the AMF on April 28, Registration Document to reflect any change in our expectations 2017 under number R.17-036 are incorporated by reference in or any change in events, conditions or circumstances, on which this Registration Document. any forward-looking statement contained in this Registration This Registration Document also includes our consolidated Document is based. We operate in a competitive and rapidly financial statements prepared in accordance with International evolving environment; it is therefore unable to anticipate al l Financial Reporting Standards, or IFRS, as adopted by the risks, uncertainties or other factors that may affect our business, European Union for the fiscal year ended December 31, 2017. their potential impact on our business or the extent to which In accordance with provisions of Article 28 of the Commission the occurrence of a risk or combination of risks could have Regulation (EC) No 809/2004 of April 29, 2004, as amended, the significantly different results from those set out in any forward- Company’s annual financial statements (IFRS) for the fiscal years looking statements, it being noted that such forward-looking ended December 31, 2015 and 2016 and the statutory auditor’s statements do not constitute a guarantee of actual results. report on the Company’s annual financial statements (IFRS) for Information on the Market and Competitive Environment the fiscal years ended December 31, 2015 and 2016 included in the Registration Document registered with the AMF on April 28, This Registration Document contains, in particular in Section 6, 2017 under number R.17-036 are incorporated by reference in “Business Overview,” information relating to our markets and this Registration Document. to our competitive position. Unless otherwise indicated, the information contained in this Registration Document related to The Registration Document may be consulted on the Company’s market shares and the size of relevant markets are our estimates website (www.gensight-biologics.com) and on the AMF’s website and are provided for illustrative purposes only. We believe that (www.amf-france.org). the information contained herein in relation to our markets and Unless otherwise indicated the selected financial information and competitive position is reliable, but the information has not been comments on the consolidated financial statements presented verified by an independent expert, and we cannot guarantee in this Registration Document have been prepared on the basis that a third-party using different methods to collect, analyze or of the consolidated financial statements prepared in accordance compute market data would arrive at the same results. with IFRS as adopted by the European Union. Risk Factors A glossary defining some of the terms used herein is appended to Investors should carefully consider the risk factors in Section 4, this Registration Document. “Risk Factors.” The occurrence of all or any of these risks could Forward-looking Statements have an adverse effect on our business, reputation, results of operation, financial condition or prospects. Furthermore, This Registration Document contains statements regarding additional risks that have not yet been identified or that are our prospects and growth strategies. These statements are not considered material by us at the date of the visa on this sometimes identified by the use of the future or conditional Registration Document could produce adverse effects. GENSIGHT BIOLOGICS – 2017 Registration Document – 5